RPG Life Sciences Q1 FY27: Growth broad-based, margins steady as execution stays in focus

Revenue from operations was Rs 195.7 crore in Q1 FY27 versus Rs 168.9 crore in Q1 FY26, a 15.8% YoY increase.

EBITDA rose to Rs 48.0 crore (24.5% margin) from Rs 40.7 crore (24.1%). PAT (excluding exceptional items) rose to Rs 30.8 crore (15.7% margin) from Rs 26.3 crore (15.6%).

Domestic Formulations contributed 68.3% (Rs 132.5 crore), International Formulations 18.0% (Rs 35.0 crore) and APIs 13.7% (Rs 26.6 crore).

The presentation notes that API growth was impacted due to a fire incident in one manufacturing block, alongside continued thrust on new customer development.

ICRA reaffirmed the long-term rating at A+ with a stable outlook and the short-term rating at A1 in June 2026.

The presentation states a project to grow the immunosuppressant portfolio to 200+ crores and initiatives to grow Naprosyn towards a 100+ crores brand, along with building the MABs portfolio.